dabigatran has been researched along with Sepsis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ay, C; Domanovits, H; Levy, JH; Sengoelge, G; Simon, A; Spiel, AO | 1 |
| Claushuis, TA; de Stoppelaar, SF; Ottenhoff, R; Roelofs, JJ; Stroo, I; van der Poll, T; Van't Veer, C | 1 |
2 other study(ies) available for dabigatran and Sepsis
| Article | Year |
|---|---|
The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran.
Topics: Acute Kidney Injury; Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation; Dabigatran; Drug Administration Schedule; Fatal Outcome; Gastrointestinal Hemorrhage; Hemofiltration; Hemorrhage; Humans; Male; Renal Dialysis; Renal Replacement Therapy; Sepsis | 2017 |
Thrombin contributes to protective immunity in pneumonia-derived sepsis via fibrin polymerization and platelet-neutrophil interactions.
Topics: Animals; Blood Coagulation; Blood Platelets; Cell Communication; Dabigatran; Extracellular Traps; Female; Fibrin; Fibrinogen; Flow Cytometry; Humans; Immune System; Immunity, Innate; Klebsiella Infections; Klebsiella pneumoniae; Lung; Mice; Mice, Inbred C57BL; Microcirculation; Neutrophils; Pneumonia, Bacterial; Sepsis; Thrombin | 2017 |